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Abstract
Bone tissue engineering has emerged as one of the leading 
fields in tissue engineering and regenerative medicine. The 
success of bone tissue engineering relies on understanding 
the interplay between progenitor cells, regulatory signals, 
and the biomaterials/scaffolds used to deliver them – 
otherwise known as the tissue engineering triad. This review 
will discuss the roles of these fundamental components with 
a specific focus on the interaction between cell behaviour 
and scaffold structural properties. In terms of scaffold 
architecture, recent work has shown that pore size can 
affect both cell attachment and cellular invasion. Moreover, 
different materials can exert different biomechanical forces, 
which can profoundly affect cellular differentiation and 
migration in a cell type specific manner. Understanding 
these interactions will be critical for enhancing the progress 
of bone tissue engineering towards clinical applications.
Keywords: Tissue engineering; bone; regeneration; 
scaffold; cell-scaffold interactions.
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Introduction
The human body’s natural reaction to trauma or injury 
is to initiate a cascade of biological processes leading 
to tissue repair. Bone tissue has excellent regeneration 
ability whereby it can repair itself in response to trauma 
or injury. However, if injury exceeds a critical size, bone 
formation is impaired and surgical intervention is required. 
There are a number of therapeutic strategies for promoting 
bone tissue regeneration. One prevalent approach is to 
transplant healthy autogenous tissue or tissue allograft. 
While significant technical advances continue to be 
made in transplantation treatments, the idea of tissue 
replacement dates back to the 16th century. Gasparo 
Tagliacozzi (1546-99) published ‘De Curtorum Chirurgia 
per Insitionem’ (The Surgery of Defects by Implantation) 
in 1597, in which he described a nose replacement that he 
had constructed from an autogenous forearm flap (Murphy 
and O’Brien, 2010; O’Brien, 2011). Today, autografts 
are still widely utilised for bone grafting while allografts 
tend to be applied more for whole organ restoration such 
as the liver, kidney and heart. Despite the life-saving 
capacity of tissue grafting, major problems still exist. For 
autogenous grafts, tissue and donor site morbidity can 
be problematic. For allografts, immune complications 
and donor availability remain challenging (Damien and 
Parsons, 1991; Arrington et al., 1996; Giannoudis et al., 
2005; Khan et al., 2005). In light of these obstacles, there 
is a strong need for the development of novel synthetic or 
bioengineered bone graft substitutes.
 Recent scientific progress in biomaterials and cell 
based therapeutics has created exceptional advances in 
the development of engineered tissues. There are three 
main components in the field of tissue engineering:
1. A scaffold that provides structure and substrate for 
tissue growth and development
2. A source of cells to facilitate required tissue formation
3. Growth factors or biophysical stimuli to direct the 
growth and differentiation of cells within the scaffold.
Taken together, these components make up what is known 
as the tissue engineering triad (Fig. 1).
 Despite early successes achieved with tissue 
engineering, many challenges are still faced in tissue 
regeneration (Rose and Oreffo, 2002). Clearly, it is critical 
to tailor the components of the tissue engineering triad 
for specific tissue applications. However, not only are 
these components individually important, understanding 
their interactions is key for successful tissue engineering. 
It is the purpose of this review to focus on the interplay 
between the three components of the tissue engineering 
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triad in the context of bone tissue engineering, with 
particular emphasis on the importance of scaffold design 
on cell attraction, migration, differentiation, and their 
subsequent tissue generation.
Biomaterials
Over the past several decades there has been an explosion 
in the range of available scaffolds in terms of composition 
and architecture to promote osteoconduction (bone mineral 
and collagen deposition) and osteoinduction (osteogenic 
differentiation) (Albrektsson and Johansson, 2001). In the 
field of scaffold design, crucial considerations include the 
biocompatibility and biodegradability of the biomaterial 
used (Hutmacher, 2000; Yang et al., 2001). The term 
biocompatible refers to the ability of a scaffold to support 
cell growth and tissue regeneration in vivo, without 
eliciting an inflammatory or immunogenic response that 
may result in its rejection. Limited local inflammation can 
promote healing and neovascularisation, however chronic 
inflammation and/or an adverse immune response can 
compromise both the implant and the patient (Babensee 
et al., 1998; Hutmacher, 2000). Ideally, biodegradation 
should occur over a period of time that allows the scaffold 
to disappear in concurrence with tissue formation, leaving 
behind repaired or regenerated tissue. This negates the 
need for a second surgery to remove the implant (Murphy 
et al., 2000; Haugh et al., 2011). In the case of drug 
delivery, degradation needs to be controlled at a rate that 
can facilitate optimal drug release. The choice of material 
and the micro- and macro-structure of that material will 
influence the biocompatibility and degradability. There are 
three major classifications of materials that have been used 
for scaffolds in bone tissue engineering: (1) ceramics, (2) 
synthetic polymers and (3) natural polymers.
 Ceramics are non-metallic compounds with a 
crystalline structure. Typically, they have a high level 
of stiffness and as a result are commonly used in bone 
tissue engineering. The most frequently used ceramics 
are calcium phosphate (CP), tricalcium phosphate 
(β-TCP), and hydroxyapatite (HA), and these materials are 
biocompatible and osteoconductive. Their biocompatibility 
is commonly attributed to their structural similarities to the 
mineral phase of bone. Nevertheless, ceramics are brittle 
materials and generally have a slow rate of degradation and 
can persist for months or years (Pilliar et al., 2001; Rizzi 
et al., 2001; Giannoudis et al., 2005).
 A number of synthetic, degradable polymers have been 
employed for bone tissue engineering. Poly(alpha-hydroxy 
Fig. 1. The three essential components that make up the tissue-engineering triad.
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acid) polymers such as polylactic acid (PLA), polyglycolic 
acid (PGA), and the co-polymer poly-DL-lactic-co-glycolic 
acid (PLGA) have shown promising pre-clinical and 
clinical findings (Amanat et al., 2007). For PLGA, the 
physical properties and degradation rates can be controlled 
by altering the monomer ratios in lactide/glycolide 
copolymers. These polymers also have FDA approval for 
specific clinical applications (Yang et al., 2001; Jiang et 
al., 2006). An attraction of synthetic polymers is an ability 
to manufacture scaffolds with characteristics tailored to 
match that of new tissue formation. However, a major 
disadvantage with many synthetic polymers is the release 
of acidic degradation by-products that can alter the pH in 
surrounding tissue. In turn, this can cause adverse tissue 
and inflammatory reactions (Yang et al., 2001; Ravindran 
et al., 2010).
 Natural polymers commonly used in tissue engineering 
include collagens, glycosaminoglycan, chitosan, hyaluronic 
acid, fibrin and elastin (Berglund et al., 2004; Ma et al., 
2004; Glowacki and Mizuno, 2008; Murphy et al., 2010), 
isolated directly from the extracellular matrix (ECM). 
Cell adhesion and subsequent cell activity is mediated by 
specific integrin-ligand interactions between the cells and 
their surrounding ECM. Some of these natural polymers 
contain surface ligands required for cell adhesion and 
proliferation (Heino, 2000). Those that lack cell specificity 
are modified to incorporate ligands that facilitate cell-ECM 
interaction (Vepari and Kaplan, 2007; Kim et al., 2008). 
Natural polymers present a more native surface relative to 
synthetic polymers; as a result, they are biocompatible and 
typically degradable with non-toxic degradation products 
(Hubbell, 1995). Limitations of natural polymers include 
their poor mechanical properties that are unsuitable for 
high strength applications as well as the relatively high 
costs associated with purification or de novo synthesis. 
Nonetheless, for orthopaedic applications natural polymers 
remain a popular choice of material. Collagen has been 
frequently explored, as it is one of the main constituents 
of the natural ECM. Outside of orthopaedics, collagen has 
achieved success in the areas of skin (Yannas et al., 1989), 
bladder (Atala et al., 2006), and airways (Macchiarini et 
al., 2008). However, to overcome the limitations associated 
with natural polymers, recent advances in scaffold design 
and fabrication have led to a paradigm shift towards 
the development of biomimetic scaffolds. Biomimetic 
scaffolds imitate the native ECM and are often utilised 
in vitro as analogues of the natural ECM to facilitate 
investigations of cell-ECM interactions and processes (Shin 
et al., 2002; Ravindran et al., 2010). More importantly, 
they provide a compromise between the mechanical and 
biological prerequisites needed to rapidly promote bone 
healing.
 An elaboration of this strategy has been to incorporate 
an additional phase into collagen scaffolds to improve the 
osteoconductivity and/or biomechanics. One example is 
the introduction of a ceramic phase, such as hydroxyapatite 
(HA) to improve the mechanical properties. Collagen-
hydroxyapatite (CHA) scaffolds have demonstrated 
improved healing of bone defects in comparison to collagen 
alone (Gleeson et al., 2010). However, other biomimetic 
scaffolds have recently emerged and are drawing new 
interest in the tissue engineering field (Shin et al., 2003; 
Radisic et al., 2006; Moutos et al., 2007; Potter et al., 
2008).
Cells in Tissue Engineering
In the context of bone tissue engineering, regeneration 
is biologically driven by progenitor cells that are able to 
form new osteoblasts. These progenitors can arise from 
within the damaged tissue or surrounding native tissues, 
or they can be exogenously supplied as part of the tissue 
engineering solution.
 An important consideration for the delivery of ex 
vivo cells is whether they are autologous, allogenic or 
xenogenic. Autologous cells are harvested directly from the 
individual undergoing repair, whereas allogenic cells are 
from a donor individual (of the same species). Xenogenic 
cells are transplanted from a different species and are less 
common in tissue engineering than in the field of whole 
organ transplantation.
 There are three principal cell therapeutic strategies 
for treating diseased or injured tissues in patients: (1) 
implanting isolated cells, (2) implanting a construct 
assembled from cells and scaffolds, or (3) in situ tissue 
regeneration by native cells.
Implantation of isolated cells
With this strategy, whole cell populations can be 
directly transplanted or isolated cells can be cultured 
and expanded ex vivo prior to re-implantation. Raw 
bone marrow transplants are an example of the former 
and have been used in the treatment of a variety of 
malignant and non-malignant haematological diseases. 
Cells within the marrow have the ability to reconstitute 
the haematopoietic system (Takahashi and Yamanaka, 
2006) and the stromal progenitors are multipotent and can 
differentiate into a variety of cell lineages (Pittenger et 
al., 1999). Consequently, transplanted marrow cells have 
been used in the regeneration of a range of complex organs 
including the liver and heart (Caplan, 2007; Timmins et al., 
2007). Recently, Gao et al. (2012) demonstrated the use 
of implanted isolated mesenchymal stem cells (MSCs) for 
bone tissue engineering. MSCs isolated from healthy donor 
mice were implanted into mutant littermates that exhibited 
skeletal defects similar to those seen in ageing bone and 
enhanced implant osteointegration (Gao et al., 2012).
Implanting a construct assembled from cells and 
scaffolds
In the context of tissue engineering and regenerative 
medicine, the use of isolated cells is not limited to direct 
replacement of damaged cells. Another method is to 
deliver a combination of whole cell isolates or ex vivo 
cultured cells seeded onto a substrate template (Lee et 
al., 2003; Levenberg et al., 2003; Kim et al., 2010). Aside 
from implantation outcomes, implant designs are still 
commonly assessed in vitro using 3D culture systems. 
These 3D culture systems can utilise primary cells from 
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the tissue to be regenerated, isolated stem/progenitor cells, 
or immortalised cell lines. These systems have been used 
to gauge the performance of engineered constructs and 
achieve incremental improvements by modification of 
scaffold (porosity, architecture, and biomaterials), drug 
delivery, or cell source.
 Established cell lines capable of extensive or indefinite 
proliferation are frequently used for in vitro investigations. 
While cell lines can demonstrate biocompatibility, these 
lines are by definition abnormal and may poorly reflect 
the in vivo behaviour of a tissue implant. Primary cells 
derived from tissue explants (whether mechanically or 
enzymatically isolated) can provide a pool of cells more 
comparable to endogenous progenitors. Nevertheless, 
3D culture models with primary cells allow optimisation 
without complications such as post-surgical infection 
and host versus graft disease (HVGD). For some tissues, 
primary cells can be challenging or impossible to isolate 
and expand (such as pancreatic islet cells), but this is rarely 
a problem for bone.
 For bone tissue engineering purposes, bone marrow-
derived MSCs remain popular due to their multipotency. 
They are capable of differentiation down multiple lineages 
including bone, cartilage, and adipose tissue (Pittenger 
et al., 1999; Krampera et al., 2006; Uccelli et al., 2008). 
Bone marrow is also considered to be the most accessible 
and enriched source of adult stem cells. Pittenger et al. 
(1999) demonstrated that cells isolated from human 
marrow aspirates were capable of remaining in a stable 
undifferentiated state in long-term cultures and could be 
induced towards osteochondral lineages when provided 
with the appropriate cues (Pittenger et al., 1999). Since 
then, extensive investigations have been carried out in 
terms of MSC characterisation and clinical potential. 
However, there are disadvantages associated with the use of 
bone marrow derived MSCs. The harvest of these cells is an 
extremely invasive procedure with donor variability being 
a prevalent issue. Furthermore, the number, differentiation 
potential and life span of these cells can decrease with 
increasing age (Nishida et al., 1999; Mueller and Glowacki, 
2001; Stenderup et al., 2003). Adipose tissue has also 
been shown to contain a population of multipotent cells, 
genetically similar to MSCs known as adipose derived stem 
cells (ADSCs). ADSCs are easily extracted from adipose 
tissue after surgical procedures such as liposuction (Fraser 
et al., 2008) and similarly to MSCs, can differentiate 
towards an osteogenic lineage when treated in osteogenic 
medium (Zuk et al., 2002) or genetically modified to 
over-express BMP-2 (Dragoo et al., 2005). An alternative, 
albeit heterologous, source is umbilical cord blood which 
can be harvested by a non-invasive approach. Similar to 
bone marrow and adipose tissue, umbilical cord blood has 
a population of multipotent MSCs that can be differentiated 
down an osteogenic lineage (Kern et al., 2006). However, 
the number of MSCs in the umbilical cord blood is 
extremely low in comparison with their population in the 
bone marrow, adipose tissue and more difficult to isolate 
(Musina et al., 2007).
 Human ES cells are a broader utility as they maintain 
pluripotency, can be induced into multiple mature somatic 
cell types (Rippon and Bishop, 2004) and can be cultured 
indefinitely in an undifferentiated state due to their ability 
to self-renew (Bishop et al., 2002; Hipp and Atala, 2008). 
However, the use of these cells is often coupled with 
complex ethical, religious, and political issues (Rippon 
and Bishop, 2004), leading to the search for alternate 
sources of stem cells that could be derived without creating 
or destroying embryos (Hipp and Atala, 2008). In 2006, 
Takahashi and Yamanaka attempted to circumvent the 
ethical issues associated with ES cells. They reported that 
enforced expression of 4 key transcription factors (OCT3/4, 
Sox2, Klf4 and c-Myc) could re-program somatic cells to 
pluripotency with similar developmental potential as ES 
cells (Takahashi and Yamanaka, 2006). These cells were 
termed induced pluripotent stem (iPS) cells. However, the 
vast differential potential of ES and iPS cells is assessed by 
the ability of these cells to form teratomas (Thomson et al., 
1998; Yu et al., 2007; Zhang et al., 2008). Consequently, 
the use of these cells in clinical practice is thus far hindered.
In situ tissue regeneration by native cells
The isolation and expansion of autologous stem cells was 
once considered to be the future of tissue engineering and 
regenerative medicine. However, challenges associated 
with cost and culture times as well as limited demonstrations 
of efficacy have led to a re-focusing of efforts to recruit 
native cells to sites of tissue damage. In order to modulate 
the migration and tissue-appropriate differentiation of 
endogenous progenitors, drugs capable of affecting 
regulatory signals or proteins involved with the regulatory 
signalling cascade can be locally delivered. As such, the 
field of controlled drug delivery via tailored biomaterials 
is currently driving many innovations in biomaterials 
(Numata and Kaplan, 2010; Yu et al., 2010; Hoffman, 
2012; Panyam and Labhasetwar, 2012;).
 Another method for modulating progenitor recruitment 
and differentiation is the application of gene therapy 
technologies. Gene therapy is a powerful tool for the 
manipulation of existing progenitors as well as the 
delivery of paracrine signals (Godbey and Atala, 2002). 
For example, cells can be engineered to produce VEGF 
to stimulate angiogenesis or rhBMP-2 to promote 
osteoblastogenesis. Gene therapy with viral and non-viral 
vectors can allow the transient or sustained release of a 
range of therapeutic factors, albeit often at high cost and 
some concerns for malignant transformation (Levenberg 
et al., 2003). Recently, there has been a surge in research 
to combine gene therapy with scaffold-based templates to 
produce gene-activated matrices (GAMs), enhancing the 
capacity for repair. The scaffold acts as a depot for the gene 
while simultaneously providing both structural support and 
a matrix for new tissue deposition (Storrie and Mooney, 
2006; O’Rorke et al., 2010; Curtin et al., 2012; Tierney et 
al., 2012a).
Regulatory Signals
Cellular behaviour is strongly influenced by biological, 
biochemical, and biophysical cues from the ECM. 
Consequently the use of regulatory signals is the third 
component of the tissue engineering triad. These include 
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biochemical and or biophysical stimuli to induce and 
regulate tissue formation both in vitro and in vivo.
 Biochemical stimuli modulate cell-signalling processes 
that regulate cellular migration, adhesion, proliferation, 
differentiation, and survival. Growth factors and cytokines 
can function locally or systemically to change patterns of 
gene expression in target cells. They can also be involved 
with up-regulating and down-regulating the synthesis of 
other growth factors and receptors. These proteins bind 
to transmembrane receptors that transduce extracellular 
signals to changes in gene expression (Griffith and 
Naughton, 2002; Rose and Oreffo, 2002; O’Brien, 2011). 
Growth factors and drugs that modulate growth factor 
signalling are broadly used within the tissue engineering 
field, although the use of recombinant factors can 
significantly add to the cost of an implant.
 For bone tissue engineering, rhBMPs are approved 
for clinical intervention and can create new bone de 
novo (Geiger et al., 2003). Other growth factors used to 
promote bone include the Insulin-like Growth Factors 
(IGFs) and Transforming Growth Factor-β proteins 
(TGF-βs). IGF-I and IGF-II have essential roles in bone 
growth, development, remodeling and repair. TGF-β, 
initially purified from platelets, stimulates matrix protein 
synthesis, has dramatic effects on osteoblast and osteoclast 
activity (Bonewald et al., 1990). Blood platelets are also 
a rich source of platelet-derived growth factor (PDGF), 
a potent stimulant of mesenchymal cell proliferation and 
migration such as fibroblasts and vascular smooth muscle 
cells (Kilian et al., 2004).
 Calcium phosphate ceramics can themselves be a 
regulatory signal in terms of bone tissue engineering. 
CP ceramics have a compositional resemblance to bone 
mineral, as such, the degradation of such biomaterials can 
elicit a biological response similar to the one generated 
during bone remodelling (Barrere et al., 2006). The 
calcium and phosphate ions released during degradation 
can induce bone cell activity (Zaidi et al., 1989; Kanatani 
et al., 1991) and may also be used as raw materials for new 
bone formation (Metsger et al., 1993; Bohner et al., 2012).
 In addition to biochemical signals, cellular behaviour 
is strongly influenced by biomechanical stimuli by 
a process known as mechano-transduction. Multiple 
systems have been developed to induce different types of 
physical stimulation to cells in culture including spinner 
flask bioreactors, flow perfusion bioreactors, dynamic 
compression bioreactors, and hydrostatic pressure 
bioreactors (Darling and Athanasiou, 2003). Provision 
of appropriate biomechanical stimulation ex vivo can 
positively influence cell differentiation and the production 
of ECM and ultimately the outcome following implantation 
(Plunkett and O’Brien, 2011). Optimised biomechanics can 
also be used to improve the cellular spatial distribution 
(Khan et al., 2005). Heterogeneous cell distribution can 
be a major obstacle to developing any three-dimensional 
(3D) tissue or organ ex vivo.
 A greater understanding of the role of the ECM in coding 
molecular/ biochemical as well as physical information 
is enabling the development of a new generation of 
biomaterials. For example, stem cell fate has been shown 
to be influenced by the stiffness of the substrate on which 
they reside (Harley et al., 2007; Murphy et al., 2012). As 
a result, scaffolds themselves have become incorporated as 
regulatory signals in the development of tissue engineered 
constructs, whereby the physical and chemical structure of 
the biomaterial is tailored for optimal cell behaviour.
Cell-Scaffold Interactions for Bone Tissue 
Engineering
Optimising the design of bioactive scaffolds is guided by 
an understanding of the behaviour and responses of cells 
cultured on these scaffolds. In the past decade, there have 
been many significant advances in the development of 
synthetic and naturally occurring biomaterials. However, 
for bone tissue engineering two major challenges exist. 
Firstly, it remains difficult to fabricate cell-permissive 
internal architectures for some biocompatible materials. 
Insufficient pore structure can lead to cellular aggregations 
around the periphery of the construct. This in turn can lead 
to premature core degradation of the construct (Kelly and 
Prendergast, 2004). Secondly, many scaffolds, particularly 
those based on first generation designs, have suboptimal 
mechanical properties, limiting their use in load bearing 
orthopaedic applications. It is necessary to overcome 
these challenges in order to facilitate the migration and 
proliferation of osteoprogenitors, and to support their 
subsequent differentiation and matrix deposition. As such, 
the interaction between scaffold architecture, scaffold 
biomechanical properties, and the cellular response remain 
areas of emerging importance in the tissue-engineering 
field.
Cell-ECM interaction
The chemical composition and physical properties of the 
natural ECM have been shown to prominently influence 
cell morphology, motility, and migration (Friedl et al., 
1998; Harley et al., 2008; Kanungo and Gibson, 2010). 
Similar to natural ECM, tissue engineering scaffolds can 
influence the cellular response in terms of cell proliferation 
and differentiation (osteoinduction), and the biomaterial 
and microarchitecture can influence chemo-attraction, 
adhesion, and migration which in turn will affect matrix 
deposition and mineralisation (osteoconduction) (Zeltinger 
et al., 2001; Tierney et al., 2009b;Keogh et al., 2010; 
Ravindran et al., 2010).
 Cell motility and migration play an important role 
in many biological processes and requires a dynamic 
interaction between the cell, its substrate and the 
cytoskeleton (Huttenlocher et al., 1995; Lauffenburger 
and Horwitz, 1996; Ridley et al., 2003). This occurs by 
means of specific ligand-integrin interactions. Cell-ECM 
interactions are accompanied by cytoskeletal action, matrix 
remodelling, and contraction, which modulate cell fate 
(Friedl et al., 1998). Whilst cell mediated contraction is 
a natural phenomenon that is essential for wound healing 
(Yannas, 2001), it can negatively affect tissue engineered 
constructs. In mechanically weak scaffolds, such as many 
natural polymers, it can lead to reduced scaffold volume. 
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This can lead to improved biomechanics, but the reduced 
scaffold size and porosity can result in difficulties fitting 
specific implant sites and subsequent osteointegration, as 
well as affecting the cellular response (Lee et al., 2001; 
Govender et al., 2002).
 The discovery of integrins in the mid 1980s altered our 
view of the natural ECM in terms of its role in the physical 
linkage and subsequent behaviour of cells (Hynes, 1987). 
Several parameters contribute to the strength of integrin-
ligand mediated cell adhesion. These include concentrations 
of adhesive ligands or substrate, number of receptors, and 
the receptor-ligand affinity. A shift in these parameters 
can have a dramatic effect on cell migration (Huttenlocher 
et al., 1995; Gumbiner, 1996; Huttenlocher et al., 1996; 
Lauffenburger and Horwitz, 1996). Altering ligand density 
has been observed to affect the strength of the cell-substrate 
interactions via differential integrin binding to adhesion 
ligands. In recent years, these effects have been translated 
in terms of 3D scaffold design. Changing the composition 
of biomaterials used in scaffold fabrication can lead to a 
difference in ligand availability and subsequent integrin 
binding. Tierney et al. (2009) demonstrated that altering the 
concentration of collagen and glycosaminoglycans (GAGs) 
in a collagen-GAG scaffold had a significant influence on 
osteoblast activity, indicating an effect of differing ligand 
availability (Tierney et al., 2009a; Tierney et al., 2012a). 
Furthermore, altering the composition of biodegradable 
scaffolds developed for cartilage repair has led to improved 
in vivo stability and increased matrix deposition (Moutos 
et al., 2007). Consequently, the composition of scaffolds 
in terms of ligand density and availability is an important 
consideration in scaffold design.
Scaffold architecture
Pore size, pore interconnectivity, and total porosity 
are essential considerations in scaffold development. 
Interconnection is essential for healthy cellular invasion, 
growth, and nutrient flow. Since the 1970s, scaffold and 
biomaterial pore size has been recognised as an essential 
consideration in tissue development (Hulbert et al., 1970). 
If the pores are too small, cell migration is limited – 
resulting in the formation of a cellular capsule around the 
edges of the scaffold. This in turn can limit diffusion of 
nutrients and removal of waste resulting in necrotic regions 
within the construct. Conversely, if the pores are too large 
there is a decrease in surface area which in turn limits 
cell adhesion. Pore size has been observed to influence 
significantly cell adhesion in vitro (O’Brien et al., 2005). 
Additionally, scaffold mean pore size significantly affects 
cell morphology and phenotypic expression (Nehrer et 
al., 1997).
 However, over the years it became evident that the 
optimal pore size varies depending on the biomaterials used 
and application of the construct. For example, in porous 
silicon nitride scaffolds pore sizes in the range of 30-80 µm 
were optimal for endothelial cell adhesion, but fibroblasts 
preferentially bound to larger pores (< 90 µm) (Salem et 
al., 2002). In contrast, for PLLA scaffolds pore sizes of 63-
150 µm represented the optimal range for vascular smooth 
muscle cells, while fibroblasts could bind a wider range of 
pore sizes including smaller pores (38-150 µm) (Zeltinger 
et al., 2001). However, over the years pores sizes in the 
range of 20-1500 µm have been reported favourably within 
the literature (Hulbert et al., 1970; Nehrer et al., 1997; Lee 
et al., 2004; Williams et al., 2005).
 In an effort to reconcile the conflicting reports, O’Brien 
et al. (2005) developed a method for identifying the 
specific surface area available for cell adhesion within 
a collagen-GAG scaffold as it related to pore-size. It 
was determined that both specific surface area and cell 
attachment decreased with increasing pore size within a 
range of 96-150 µm (O’Brien et al., 2005). A more recent 
study expanded the range to 85-325 µm and demonstrated 
a bimodal effect of pore size on cell attachment (Murphy 
et al., 2010). Within the lower range of pore sizes (85-
190 µm), a significant peak in cell number was observed 
in pore size of 120 µm – similar to the findings of O’Brien 
et al. (2005). However, when this pore range was expanded 
the largest pore size facilitated the highest cell attachment 
even though specific surface area decreased (Murphy et 
al., 2012). One interpretation of these findings is that the 
lower peak results from optimising the specific surface 
area and attachment, but that a second peak emerges from 
an improved potential for cell migration and proliferation. 
More recent studies have examined the effect of pore size 
on long term tissue development. Siccheri et al. (2012) 
investigated tissue interaction in vivo within PLGA-
CaP scaffolds with pores in the range of 470-1200 µm. 
Increased bone formation and vessel number was observed 
within pores in the range of 470-590 µm. Although this 
paper does not identify the lower limits of the optimal pore 
range for tissue formation, it is one of the first to identify 
an optimal pore range for tissue formation (Sicchieri et al., 
2012).These papers reflect the first important step towards 
fully understanding the relationship between scaffold pore 
size and resultant cell and tissue behaviour.
 Different cell types exhibit a preference for adhesion 
to scaffolds with different mean pore sizes, due to the 
characteristic size of the cell. When migrating through a 
porous network, cells use a bridging mechanism whereby 
they use neighbouring cells as support to bridge across 
pores larger than the individual cell (Salem et al., 2002). 
However, if pore size greatly exceeds the dimensions of 
a cell, the cell can only spread along the struts and this 
can influence cell migration and migration speed (Reilly 
and Engler, 2010). Lowery et al. (2010) highlighted these 
changes in cell conformation with changing pore size in 
woven polycaprolactone (PCL) scaffolds. As pore size 
increased, cells began to align along single fibres instead 
of attaching to multiple fibres (Lowery et al., 2010). Pore 
size within a scaffold determines the number of struts and 
the density of ligands available for cell adhesion. Thus, 
as pore size decreases there is more specific surface area 
for cell to adhere to (O’Brien et al., 2005). However, this 
denser network of struts limits choice in cells’ direction of 
their movement and creates a greater resistance to scaffold 
penetration (Harley et al., 2008).
 Speed is often the metric of choice to quantify the 
ability of cells to migrate (Lauffenburger and Horwitz, 
1996; Ridley et al., 2003). However, it does not provide 
126 www.ecmjournal.org
CM Murphy  et al.                                                                                                                     Cell-scaffold interactions
information about the direction or distribution of this 
motion (Zaman et al., 2007). Cells travelling through 
larger pores may migrate slower, but their directional 
movement allow them to travel further into the scaffold 
(Fig. 2). In summary, it has been shown that larger pore size 
can overcome the advantages of specific surface area by 
increased cell migration and scaffold infiltration (Murphy 
et al., 2010).
 Scaffold porosity, the percentage void space within a 
solid (Karageorgiou and Kaplan, 2005), and pore size are 
intrinsically coupled. Whilst pore size is essential for cell 
attachment, proliferation and migration, porosity influences 
nutrient delivery and waste removal through a construct. It 
is generally accepted that the higher the porosity the better 
for construct development. Depending on the biomaterial 
used, an increase in porosity can lead to a decrease in 
mechanical properties. This is generally a greater concern 
in natural biomaterials such as collagen, alginate-based 
substrates and chitosan, as they are mechanically weaker 
materials. However, there are a number of crosslinking 
techniques that can be utilised to strengthen without 
affecting porosity (Haugh et al., 2009).
Mechanical properties
A scaffold’s mechanical properties are derived from its 
composition and architecture. Beyond the previously 
discussed effects of scaffold architecture on cell migration, 
the capacity of a scaffold to respond to mechanical force 
can modulate the cellular response. These mechano-
regulatory signals remain poorly understood, but may be 
an important consideration for future tissue engineering 
scaffold design.
 Mechano-transduction is a process whereby cells 
transduce or convert physical force-induced signals into 
biochemical signals that are integrated into appropriate 
cellular responses (Ko and McCulloch, 2001; Huang et 
al., 2004). Numerous molecules, cellular components and 
extracellular structures have been shown to be involved 
in mechanochemical transduction. These transduction 
elements include cell-ECM and cell-cell adhesions, 
membrane components, cytoskeletal filaments and nuclear 
structures. A current challenge is trying to understand 
how cells orchestrate all these transduction mechanisms 
to produce specific responses to mechanical signals. 
Not all anchorage-dependent cells respond to substrate 
stiffness in the same way. However, MSCs, fibroblasts 
and endothelial cells have demonstrated increased cell 
adhesion, spreading and proliferation on stiffer substrates 
(Discher et al., 2005; Yeung et al., 2005). Cell migration 
has also shown to be influenced by stiffness gradients. 
Integrins provide a mechanical link between the ECM and 
the actomyosin cytoskeleton of cells. Integrins can trigger 
signalling transduction cascades and induce focal adhesion 
formations as a result of ECM ligand binding and associated 
changes in receptor conformation. Force application 
to bound integrins promotes focal adhesion assembly, 
which in turn promotes actin filament polymerisation and 
induces cytoskeletal contraction. Contractile forces are 
generated by the ubiquitous cross-bridging interactions 
of actin and myosin-II filaments in stress fibres (Fig 3A). 
These forces are transmitted to the substrate as traction 
forces. It is through these forces that cells are able sense 
their surrounding matrix and can distinguish subtle 
changes in matrix elasticity (Zajac and Discher, 2008). 
Although living cells might sense and respond to force 
locally through individual mechanosensitive molecules, 
they integrate physical and chemical signals at the whole 
cell level before they respond. As such, mechanical 
Fig. 2. Illustration on the effect of specific surface area in small pores (A) and large pores (B) on cell migration. 
Arrows indicate the direction of migration of cell and the distance travelled assuming the rate of cell migration 
is constant.
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forces generated with cell-ECM or cell-cell adhesions can 
influence embryogenesis and tissue formation (Evans et al., 
2009). The mechanical properties of native tissues are very 
diverse and can vary, for example, from soft brain tissue 
(0.1 kPa) to pre-calcified bone (100 kPa) to rigid compact 
bone (20 GPa) (Fig. 3B) (Zysset et al., 1999; Flanagan et 
al., 2002). As such, naïve stem cells are exposed to a range 
of matrix elasticity in vivo.
 In 2006, a study by Engler et al. indicated a key 
relationship between substrate stiffness and MSC 
differentiation whereby MSCs sense their surrounding 
matrix elasticity and transduce that information into 
morphological changes and lineage specification. Matrix 
elasticity was mimicked with inert polyacrylamide 
(PAAm) gels. Elasticity was altered via crosslinking with 
different concentrations of bis-acrylamide and adhesion 
was provided by collagen type I coating of the gels. 
Utilising this elastically tuneable system it was shown 
that matrix can specify the lineage of naïve stem cells 
towards neurons, myoblasts and osteoblasts respectively as 
stiffness increased. In addition, non-muscle myosin II (NM 
II) was identified as an integral component of the cell’s 
ability to couple matrix stiffness to lineage specification 
(Engler et al., 2006). This study was the first to highlight 
importance of elasticity-directed differentiation as a novel 
and surprisingly sensitive cell regulator. Although once 
considered a cornerstone in literature for the effect substrate 
stiffness on stem cell fate, recent studies have demonstrated 
that there are other stem-cell-niche interactions guiding 
cell-substrate stiffness driven differentiation that must 
be taken into consideration. Trappmann et al. (2012) 
demonstrated that, similarly to the findings of Engler et al. 
(2006), MSC differentiation was regulated by the elastic 
modulus of PAAm gels. However, MSC differentiation was 
unaffected by polydimethylsiloxane (PDMS) gel stiffness. 
Furthermore, when PMDS gels were cultured with human 
epidermal stem cells, differentiation was unaffected. On 
PAAm gels, epidermal stem cell differentiation was only 
affected on gels of low elasticity (Trappmann et al., 2012). 
Similar to Engler et al. (2006), these gels were coated with 
collagen type I and changing the collagen crosslinking 
concentration altered stem cell differentiation on both gel 
types. Contradictory to previous findings, Trappmann et 
al. (2012) concluded that the feedback mechanism that 
drives cell-fate decisions is directed by the mechanical 
force exerted by the stem cells on the collagen fibres as 
opposed to the gels themselves. These studies demonstrate 
that stem cells-ECM mechano-forces and subsequent cell 
responses vary with differing cell types and substrates, 
highlighting the complicated nature of these interactions.
Fig. 3. Illustrations depicting the attachment of a cell to a soft (A) and stiff (B) substrate and the resultant cytoskeletal 
formations, adapted from Zajac et al. (2008).
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 Many of these studies have been carried out on 
polymer gels that do not recapitulate the normal 3D 
environment encountered by cells in porous engineered 
scaffolds. Recently, focus has shifted to changes sensed 
by cells within the elastic modulus of porous scaffolds 
(Murphy et al., 2012). Micro forces created by cellular 
contraction receive different mechanical-regulatory 
feedback, dependent on a scaffold’s capacity for 
deformation. Previously, it has been shown that collagen-
GAG scaffold architecture influences the fate of MSCs 
whereby the stiffest collagen-GAG scaffolds (1.5 kPa) 
directed naïve MSCs towards on osteogenic lineage and 
the most compliant collagen-GAG scaffolds (0.5 kPa) 
directed the MSCs towards a chondrogenic lineage. It is 
interesting to note that the stiffness range utilised in this 
study is significantly limited in comparison to the studies 
carried out on 2-D substrates and gels. Yet, a significant 
influence on stem cell fate was observed (Murphy et al., 
2012). This highlights the intricate relationship between 
cells and 3D porous scaffolds. What is determined as the 
elastic modulus of a whole scaffold, may not appropriately 
reflect the forces placed on a single cell on an individual 
struts (Harley et al., 2007). This area of research is still 
in its infancy and these mechano-biological relationships 
and the cell pathways they modulate need to be better 
understood, both in 2D and 3D environments, in order to 
manipulate stem cell differentiation for in vitro and clinical 
applications.
Conclusions
Tissue engineering is aimed at different applications, 
including implantation and drug delivery. Although 
individually important, success depends on the convergence 
of the three components of the tissue engineering triad. The 
utility of each component ultimately relies upon the criteria 
required for the specific application.
 Subtle changes in scaffold architecture have significant 
effects on cellular activity. Interestingly, there is a dual 
relationship between scaffold pore size and cell behaviour. 
Increased surface area, provided by small pores, may have 
a beneficial effect on cell adhesion. However, improved 
cellular infiltration and migration, facilitated by larger 
pores, outweighs this effect. Recent advances in the cell 
biology of the ECM and ECM receptors have provided 
new and important ways of thinking about the interplay 
between cells and scaffolds, whereby scaffold mechanical 
properties and composition have been shown to influence 
integrin-ligand interactions, thus affecting cell morphology 
and differentiation. These fundamental studies have 
demonstrated the importance of tailoring scaffold micro-
architecture, cell type and regulatory signals for tissue-
specific applications.
 In summary, continuing efforts are being made towards 
developing a clinically functioning tissue-engineered 
scaffold. Advancing our way of understanding and thinking 
about the interplay between cells and scaffolds will 
enhance our progression towards clinical applications.
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